Double-blind, placebo-controlled, parallel group study to evaluate safety and efficacy of oral fampridine-SR (10 mg b.i.d.) in patients with multiple sclerosis.

Trial Profile

Double-blind, placebo-controlled, parallel group study to evaluate safety and efficacy of oral fampridine-SR (10 mg b.i.d.) in patients with multiple sclerosis.

Completed
Phase of Trial: Phase III

Latest Information Update: 11 Feb 2016

At a glance

  • Drugs Fampridine (Primary)
  • Indications Multiple sclerosis
  • Focus Registrational; Therapeutic Use
  • Most Recent Events

    • 25 Apr 2012 Results presented at the 64th Annual Meeting of the American Academy of Neurology, according to an Acorda Therapeutics media release.
    • 27 Feb 2012 Primary endpoint changed as reported by ClinicalTrials.gov (Extention trial NCT00649792).
    • 27 Feb 2012 Primary endpoint changed as reported by ClinicalTrials.gov (Extention trial NCT00649792).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top